Skip to content

A clinical trial to study the effect and safety of Javetri in patients with Abnormal Lipid Profile

Evaluation of efficacy and safety of Javetri (Myristica fragrans) in patients of dyslipidaemia

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024185
Enrollment
60
Registered
2020-03-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E788- Other disorders of lipoprotein metabolism

Interventions

Intervention1: Javetri: 500mg to be given in the form of tablets 2 tab twice a day Control Intervention1: Placebo: 500mg roasted rice to be given in the form of tablets 2 tab twice a day

Sponsors

School of Unani Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Known cases of dyslipidemia with any one of the following: 1. Total Cholesterol Level >200 mg/dl 2. Low Density Lipoprotein Cholesterol Level >130mg/dl 3. Serum Triglycerides Level >150 mg/dl 4. High Density Lipoprotein

Exclusion criteria

Exclusion criteria: 1. Low Density Lipoprotein Cholesterol Level >160mg/dl. 2. Serum Triglycerides Level >= 1000mg/dl. 3. Pregnant and Lactating women 4. Patients suffering with CKD, CAD, CLD or uncontrolled DM, Thyroid Disorder. 5. Patient having immune-compromised status. 6. Patient using lipid lowering drugs or dietary supplements with the last 3 weeks. 7. Oral contraceptives & Corticosteroids. 8. Use of Alcohol or any other drug abuse. 9. Neurological disorders like epilepsy or psychiatric disorders. 10. Patient having history of Pancreatitis. 11. Terminally ill Patient.

Design outcomes

Primary

MeasureTime frame
1.Changes in the levels of Total cholesterol,LDL,serum triglyceride and HDL-C 2.Safety Parameters CBC with ESR,LFT,KFT,Blood sugar Fasting and PP, Urine R/M Timepoint: (0), 14th day, 28th day, 42nd day, 56th day, 60th day and 84th day.

Secondary

MeasureTime frame
Estimation of anti-oxidant level in vivo and level of NiacinTimepoint: (0),day and 84th day

Countries

India

Contacts

Public ContactDr Azhar Jabin

School of Unani Medical Education and Research

jabeendr@gmail.com9899315252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026